ArticleESMO open2025

Outcomes of immune checkpoint inhibitor rechallenge in advanced urothelial carcinoma: results from a global real-world evidence study.

B A Maiorano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.